PlainMeds rankings
The largest changes in FAERS reports, 2024 to 2025
Reports received in 2025 against 2024, medicines with 300 or more reports in 2024. The most: foscarbidopa and foslevodopa (+1,022% change in reports received). A FAERS report does not show that the medicine caused the event; counts follow use and reporting. A change often follows a lawsuit, a label change or a new use.
The ranking
| Rank | Medicine | Change in reports received |
|---|---|---|
| 1 | Foscarbidopa and foslevodopa379 to 4,251 | +1,022% |
| 2 | Bimekizumab2,720 to 10,927 | +302% |
| 3 | Sotatercept-csrk774 to 2,250 | +191% |
| 4 | Medroxyprogesterone1,016 to 2,763 | +172% |
| 5 | Norgestrel349 to 937 | +168% |
| 6 | Amivantamab592 to 1,482 | +150% |
| 7 | Perfluorohexyloctane398 to 918 | +131% |
| 8 | Vamorolone377 to 848 | +125% |
| 9 | Capsaicin333 to 731 | +120% |
| 10 | Enfortumab vedotin1,165 to 2,437 | +109% |
| 11 | Zuranolone379 to 753 | +99% |
| 12 | Sparsentan1,221 to 2,395 | +96% |
| 13 | Tirzepatide33,048 to 62,302 | +89% |
| 14 | Bupropion and naltrexone1,327 to 2,412 | +82% |
| 15 | Relugolix5,773 to 10,314 | +79% |
| 16 | Ublituximab1,012 to 1,782 | +76% |
| 17 | Dostarlimab422 to 742 | +76% |
| 18 | Tildrakizumab339 to 591 | +74% |
| 19 | Abaloparatide3,634 to 6,306 | +74% |
| 20 | Talquetamab508 to 873 | +72% |
| 21 | Nirsevimab450 to 772 | +72% |
| 22 | Vutrisiran516 to 868 | +68% |
| 23 | Varenicline374 to 616 | +65% |
| 24 | Lotilaner776 to 1,253 | +61% |
| 25 | Ivermectin409 to 626 | +53% |
| 26 | Sevoflurane447 to 684 | +53% |
| 27 | Fruquintinib1,193 to 1,820 | +53% |
| 28 | Momelotinib381 to 579 | +52% |
| 29 | Magnesium citrate682 to 1,033 | +51% |
| 30 | Vonoprazan1,446 to 2,176 | +50% |
| 31 | Pimavanserin7,197 to 10,500 | +46% |
| 32 | Fenfluramine898 to 1,307 | +46% |
| 33 | Finasteride5,098 to 7,349 | +44% |
| 34 | Isavuconazonium363 to 517 | +42% |
| 35 | Tenapanor355 to 504 | +42% |
| 36 | Darolutamide1,406 to 1,986 | +41% |
| 37 | Insulin lispro6,289 to 8,874 | +41% |
| 38 | Pancrelipase amylase and pancrelipase lipase and pancrelipase protease4,223 to 5,909 | +40% |
| 39 | Semaglutide14,310 to 20,013 | +40% |
| 40 | Cenegermin2,274 to 3,179 | +40% |
| 41 | Sodium oxybate1,124 to 508 | -55% |
| 42 | Asfotase alfa2,432 to 1,084 | -55% |
| 43 | Mometasone and olopatadine659 to 285 | -57% |
| 44 | Vemurafenib467 to 199 | -57% |
| 45 | Niraparib2,062 to 878 | -57% |
| 46 | Benzoyl peroxide446 to 183 | -59% |
| 47 | Ranibizumab1,343 to 543 | -60% |
| 48 | Salicylic acid906 to 350 | -61% |
| 49 | Entrectinib467 to 172 | -63% |
| 50 | Monomethyl fumarate318 to 110 | -65% |
| 51 | Evolocumab25,531 to 7,905 | -69% |
| 52 | Adapalene4,124 to 1,242 | -70% |
| 53 | Alectinib1,856 to 541 | -71% |
| 54 | Nirmatrelvir and ritonavir9,041 to 2,608 | -71% |
| 55 | Nirogacestat563 to 156 | -72% |
| 56 | Efgartigimod alfa1,668 to 451 | -73% |
| 57 | Estradiol and norethindrone and relugolix481 to 108 | -78% |
| 58 | Alteplase2,836 to 603 | -79% |
| 59 | Voxelotor1,436 to 141 | -90% |
| 60 | Elacestrant3,661 to 329 | -91% |
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, read October 8, 2026
What it cannot show
A FAERS report does not show that the medicine caused the event; counts follow use and reporting. A change often follows a lawsuit, a label change or a new use.